Hypothalamic Pharmacology · Module 2 of 4

GnRH Analogs in Clinical Practice

Agonists, antagonists, oral agents, and clinical applications

The testosterone flare from GnRH agonist depot initiation is mechanistically unavoidable — the analog binds the GnRH receptor with higher affinity than native GnRH, produces the same Gq-IP3-calcium signal, and drives an LH surge that raises testosterone 50–80% above baseline for 1–2 weeks; flare prevention with bicalutamide 50 mg daily beginning 7–14 days before the first injection is mandatory in patients with vertebral metastases, bulky nodal disease, or severe urinary obstruction, where testosterone surging can precipitate spinal cord compression or ureteral obstruction.
GnRH antagonists (degarelix, elagolix, relugolix) bypass the flare entirely by competitively blocking the receptor without activation — degarelix achieves castrate testosterone in >96% of patients within 3 days; relugolix (HERO trial) achieved castrate testosterone in 96.7% at 48 weeks with a 54% lower MACE rate versus leuprolide, making it the preferred agent in patients with established cardiovascular disease or prior MI/stroke within 6 months.
Elagolix and relugolix have distinct drug interaction profiles that must not be conflated — elagolix is a major CYP3A4 substrate (strong CYP3A4 inhibitors contraindicated at the 200 mg BID dose; rifampin reduces efficacy; cyclosporine raises levels via OATP1B1 inhibition), while relugolix is not a significant CYP3A4 substrate but is a P-gp/BCRP substrate (amiodarone, clarithromycin, verapamil increase exposure up to 4-fold — contraindicated).
Add-back therapy for GnRH agonist-treated endometriosis exploits the estrogen threshold principle — endometriosis implants require estradiol above ~20 pg/mL to grow, while bone mineral density loss begins below ~30–40 pg/mL; maintaining estradiol in the 20–40 pg/mL window with norethindrone acetate 5 mg daily (with or without low-dose estrogen) preserves bone without reigniting endometriosis, allowing treatment extension beyond the standard 6-month bone-protection limit.
ADT monitoring is protocol-driven and time-sensitive — baseline ECG (if on QT-prolonging drugs), DEXA, fasting glucose, and lipids before starting; testosterone and PSA at each injection visit; DEXA repeat at 12 months; bone-protective therapy (zoledronic acid or denosumab) for T-score below −1.0 or fracture history; aerobic and resistance exercise for all patients to attenuate metabolic syndrome; hot flashes (50–80% incidence) managed with venlafaxine, gabapentin, or medroxyprogesterone acetate.

Abbreviations: GnRH = gonadotropin-releasing hormone · LH = luteinizing hormone · FSH = follicle-stimulating hormone · ADT = androgen deprivation therapy · PSA = prostate-specific antigen · MACE = major adverse cardiovascular events · PLGA = poly(lactic-co-glycolic acid) · P-gp = P-glycoprotein · BCRP = breast cancer resistance protein · OATP1B1 = organic anion-transporting polypeptide 1B1 · HPG = hypothalamic-pituitary-gonadal · BMD = bone mineral density · DEXA = dual-energy X-ray absorptiometry · CPP = central precocious puberty

GnRH Agonist vs. Antagonist — Mechanism and Key Differences

Feature	GnRH Agonist Depot	Injectable Antagonist (Degarelix)	Oral Antagonist (Relugolix)
Mechanism	Continuous receptor activation → desensitization and downregulation	Competitive receptor blockade — no activation	Competitive receptor blockade — no activation
Testosterone flare	YES — cover with bicalutamide 50 mg daily ×4 weeks	NO — castrate levels within 3 days	NO — suppression within days; no loading surge
Onset of castration	3–4 weeks	Within 3 days (>96% at day 3)	Within days (96.7% sustained castration at 48 weeks — HERO)
Dosing	Monthly to quarterly IM or SC depot	240 mg SC loading (day 1) → 80 mg SC monthly	360 mg loading dose → 120 mg once daily oral
Key adverse effect	QTc prolongation; metabolic syndrome; slow testosterone recovery (months to >1 year)	Injection site reactions in 35–40% (pain, erythema, nodule)	54% lower MACE vs. leuprolide (HERO trial); fast recovery (t½ ~25 h)
Preferred when	Established practice; cost-sensitive; quarterly dosing preferred	Rapid suppression needed; flare risk high; no daily adherence required	High CV risk; prior MACE <6 months; fertility recovery desired after treatment

GnRH Agonist Depot Formulations

Leuprolide — PLGA Microsphere or Atrigel

Monthly to 6-Month IM / SC

1-month: 7.5 mg IM/SC · 3-month: 22.5 mg · 4-month: 30 mg · 6-month: 45 mg
Lupron Depot (IM microsphere); Eligard (SC atrigel gel)
Pediatric CPP: 0.3 mg/kg IM q4 weeks (minimum 7.5 mg)
Confirm castrate testosterone (<50 ng/dL) before each injection; non-castrate level occurs in 4–13% → investigate technique and site rotation

Goserelin — Biodegradable SC Rod

28-Day or 84-Day SC Implant

1-month: 3.6 mg · 3-month: 10.8 mg — placed via trocar in anterior abdominal wall
Must be subcutaneous — IM placement prevents controlled release
Renally eliminated (~90%); no dose adjustment for mild-moderate renal impairment
No reconstitution required — prefilled implant device

Triptorelin / Histrelin — IM Depot or Annual Implant

Monthly, 3-Month, or 6-Month

Triptorelin: 3.75 mg (1-month) / 11.25 mg (3-month) / 22.5 mg (6-month) IM
Hepatic peptidase metabolism; renal elimination
Histrelin (Supprelin LA): annually replaced SC implant for CPP — continuous agonist delivery without repeated injections
Suppression confirmed by stimulated LH <2 IU/L at 30–60 min post-GnRH stimulus

Oral GnRH Antagonists — Drug Interaction Profiles

Elagolix (Orilissa) — CYP3A4 Substrate

Dose-Dependent Partial or Complete HPG Suppression

Oral bioavailability ~57%; metabolized primarily by CYP3A4 (secondary CYP2C8)
150 mg once daily: partial suppression → endometriosis pain (up to 24 months)
200 mg twice daily: near-complete suppression (max 6 months without add-back; up to 12 months with norethindrone acetate 1 mg add-back)
Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin): 200 mg BID dose contraindicated
CYP3A4 inducers (rifampin, carbamazepine): reduce efficacy
Cyclosporine (OATP1B1 inhibitor): increases elagolix levels
P-gp inhibitor: may increase digoxin exposure

Relugolix (Orgovyx / Myfembree) — P-gp Substrate

Immediate, Reversible Suppression — No CYP3A4

Oral bioavailability ~12%; t½ ~25 h; once-daily dosing
Prostate cancer: 120 mg once daily (360 mg loading dose)
Fibroids / endometriosis: Myfembree (40 mg + estradiol 1 mg + norethindrone 0.5 mg once daily)
Strong P-gp inhibitors (amiodarone, clarithromycin, verapamil, itraconazole): exposure up to 4× — contraindicated
P-gp inducers (rifampin, carbamazepine, St. John's wort): reduce efficacy
NOT a major CYP3A4 substrate — differentiates from elagolix
HERO trial: 54% lower MACE vs. leuprolide; rapid testosterone recovery after stopping

Clinical Applications by Indication

Indication	First-Line Agent(s)	Key Considerations	Monitoring
Prostate cancer (ADT)	Leuprolide depot or relugolix (preferred with high CV risk)	Cover agonist flare with bicalutamide ×4 weeks; target testosterone <50 ng/dL (ideally <20); intermittent ADT acceptable for biochemically recurrent non-metastatic disease	PSA, testosterone at each injection; fasting glucose, lipids, DEXA at baseline and 12 months
Endometriosis	Leuprolide or goserelin depot; elagolix oral (dose-titratable)	Agonist monotherapy limited to 6 months without add-back; add-back maintains estradiol 20–40 pg/mL; elagolix 150 mg may be used up to 24 months	BMD at 6–12 months with prolonged use; symptom reassessment
Uterine fibroids	Myfembree (relugolix combination) or leuprolide depot preoperatively	Fibroid regrowth within 3–6 months of stopping agonist monotherapy; Myfembree built-in add-back enables extended use	BMD with prolonged use; symptom and bleeding assessment
Central precocious puberty	Leuprolide depot-Ped or histrelin annual implant	Confirm suppression: stimulated LH <2 IU/L; bone age X-ray annually; halt therapy at appropriate bone age to allow pubertal completion	Growth velocity, bone age, stimulated LH q3–6 months

ADT Adverse Effects — High-Yield Monitoring Protocol

QTc prolongation: testosterone suppression prolongs corrected QT by ~10–20 ms; concurrent QT-prolonging drugs (antiarrhythmics, certain antipsychotics, fluoroquinolones, azithromycin, methadone) amplify this substantially. Obtain baseline ECG before starting ADT in any patient on a QT-prolonging drug; repeat at 1–3 months. Contraindicate GnRH agonists if baseline QTc exceeds 500 ms without cardiology input.

Bone loss: BMD declines ~2–3% per year at lumbar spine and femoral neck. Calcium 1,000–1,200 mg daily and vitamin D 800–1,000 IU daily for all patients. DEXA at baseline and 12 months for continuous ADT. Add zoledronic acid 4 mg IV every 12 months or denosumab 60 mg SC every 6 months for T-score below −1.0, prior fragility fracture, or ADT duration exceeding 12 months.

Metabolic syndrome: visceral adiposity, insulin resistance, dyslipidemia, and hypertension develop predictably. ADT increases type 2 diabetes risk ~40% and major cardiovascular event risk 10–20% over 1–5 years. Prescribe aerobic and resistance exercise for all patients. Screen for diabetes and cardiovascular risk factors at baseline and every 3–6 months. Hot flashes (50–80% incidence): venlafaxine, gabapentin, or medroxyprogesterone acetate.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 40: Estrogens, Progestins, and the Female Reproductive Tract	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 44: Estrogens and Progestins	McGraw-Hill; 2023
Conn PM, Crowley WF Jr.	Gonadotropin-releasing hormone and its analogs	N Engl J Med. 1991;324(2):93–103
Seidenfeld J, Samson DJ, Hasselblad V, et al.	Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis	Ann Intern Med. 2000;132(7):566–577
Higano CS.	Side effects of androgen deprivation therapy: monitoring and minimizing toxicity	Urology. 2003;61(2 Suppl 1):32–38
Levine GN, D'Amico AV, Berger P, et al.	Androgen-deprivation therapy in prostate cancer and cardiovascular risk	Circulation. 2010;121(6):833–840
Sharifi N, Gulley JL, Dahut WL.	Androgen deprivation therapy for prostate cancer	JAMA. 2005;294(2):238–244
Klotz L, Boccon-Gibod L, Shore ND, et al.	The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer	BJU Int. 2008;102(11):1531–1538
Boehm U, Bouloux PM, Dattani MT, et al.	Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism — pathogenesis, diagnosis and treatment	Nat Rev Endocrinol. 2015;11(9):547–564
Taylor HS, Giudice LC, Lessey BA, et al.	Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist	N Engl J Med. 2017;377(1):28–40
Giudice LC, As-Sanie S, Arjona Ferreira JC, et al.	Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain (SPIRIT 1 and 2)	Lancet. 2022;399(10343):2267–2279
Shore ND, Saad F, Cookson MS, et al; HERO Study Investigators.	Oral relugolix for androgen-deprivation therapy in advanced prostate cancer	N Engl J Med. 2020;382(23):2187–2196
Vercellini P, Vigano P, Somigliana E, Fedele L.	Endometriosis: pathogenesis and treatment	Nat Rev Endocrinol. 2014;10(5):261–275
Carel JC, Eugster EA, Rogol A, et al; ESPE-LWPES GnRH Analogs Consensus Conference Group.	Consensus statement on the use of gonadotropin-releasing hormone analogs in children	Pediatrics. 2009;123(4):e752–e762